Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Researchers describe new technique for cataloging RNA targets in rare brain disease


RNA, often thought of as merely the chemical messenger that helps decode DNA’s genetic instructions for making proteins, can itself play a crucial role in regulating protein expression. Not surprisingly, this regulation occurs through proteins that bind to RNA. All cells in the body, especially nerve cells in the brain, use and regulate RNA in an exquisite fashion.

Scientists have previously shown that defects in RNA binding underlie several human brain disorders, but their RNA targets have been a mystery. Researchers at Rockefeller University have now developed a method that allows scientists, for the first time, to develop complete lists of RNAs that are regulated by RNA binding proteins.

According to the researchers, the method will generally be useful for scientists studying other diseases that result from defects in RNA regulation, including several autoimmune diseases, spinal muscular atrophy, and Fragile X mental retardation.

Reporting in the Nov. 14 issue of the journal Science, a team of scientists led by Robert B. Darnell, M.D., Ph.D., a professor at Rockefeller and an investigator at the Howard Hughes Medical Institute, showed that their new technique, called CLIP, can rapidly identify all the RNAs that bind to a protein that has been linked to the brain disorder POMA, or paraneoplastic opsoclonus myoclonus ataxia. These experiments were able to show that a protein called Nova plays a critical role in regulating alternative splicing within the brain.

"We have developed and validated a new methodology we term CLIP to help scientists interested in the role of RNA binding proteins in biology and disease," says Darnell. "We used CLIP to show that an RNA-binding protein called Nova regulates a biologically coherent -- that is, not a random -- set of RNAs whose proteins function at the synapse of nerve cells in the brain. This finding may help us better understand and treat the variety of diseases that involve the misregulation of RNA-binding proteins."

The scientists first became interested in Nova because the protein plays a key role in one of the paraneoplastic neurological disorders (PNDs) that the Darnell lab studies. Patients suffering from the PND termed POMA are unable to inhibit movement and suffer uncontrollable shaking. PNDs develop when cancer cells in the body prompt a tumor immune response that makes its way across the blood-brain barrier and disrupts the normal function of brain cells.

The brain is known as an "immune-privileged" site, meaning that proteins expressed only in the brain are not screened by the immune system as it goes through the process of learning which proteins are "self" and which are "foreign."

When a brain protein is expressed in a tumor elsewhere in the body, the immune system sees it as a foreign protein and mounts a strong response against it. This immune response, while good for eliminating the tumor, sometimes makes its way into the brain where it can attack those neurons that express the protein. In the case of POMA, the protein is Nova.

The exact nature by which the immune system attacks the brain is unclear, but POMA patients have high levels of antibodies against Nova in their spinal fluid. These antibodies bind a segment of Nova called the KH domain and inhibit Nova’s interaction with RNA. Researchers suspect that the profound dysfunction of body movement that afflicts people with POMA is caused at least in part by a direct inhibition of RNA binding by Nova antibodies.

In 2000, Darnell and his colleagues, including Kirk B. Jensen, Ph.D., co-first author of the new Science paper, provided the first evidence that Nova is responsible for regulating RNA splicing in nerve cells.

RNA splicing is the process by which the initial RNA copy of any gene, known as pre-mRNA, is pieced together to produce a mature mRNA that codes for cellular proteins. In alternative splicing, different pieces of this pre-mRNA, called exons, are stitched together to produce different mRNAs, and thus different proteins. By regulating alternative splicing cells can produce a wide variety of proteins from a finite number of genes. This capacity is believed to critical to the complex workings of human cells such as those found in the neurons of the brain.

Nova was the first RNA binding protein discovered to regulate alternative splicing specifically in the brain.

"The finding that Nova regulates RNA splicing in neurons was satisfying as a proof of principle and raised interesting questions about Nova’s function in disease," says Darnell. "More generally for Nova, and for all RNA-binding proteins that are important in biology and human disease, what we really want to know is what is the full array of RNAs that these proteins bind to -- the complete list."

To compile the complete list of RNAs to which Nova binds, Jensen and co-first author Jernej Ule combined a pair of standard techniques in the arsenal of biochemists -- photo cross-linking and immunoprecipitation -- with the use of brain tissue and a number of special techniques to create a new method called CLIP.

CLIP works by exposing cells to ultraviolet (UV) light, which causes very strong chemical bonds -- "irreversible links," says Jensen --to develop between RNA binding proteins and any RNAs with which they are in direct contact. After exposing mouse brain to UV light, the scientists then used a technique called immunoprecipitation, which uses antibodies to purify the samples. In the Science study, the Rockefeller scientists took serum containing Nova antibodies from POMA patients studied at The Rockefeller University Hospital for the immunoprecipitation step.

Using CLIP, the researchers identified an astounding set of 340 Nova RNA "tags": short stretches of RNA that harbor binding sites for Nova. By comparison, research using previously available methods, involving work done over the last seven years, had resulted in three RNA targets of Nova.

Darnell and colleagues focused on 18 CLIP tags that were adjacent to alternatively spliced exons. Of these, seven CLIP tags correctly identified exons where alternative splicing was misregulated in nerve cells in the brains of Nova knockout mice. These laboratory animals lack the gene for the Nova protein.

"Our data suggest that the neuron-specific protein Nova is the predominant -- and perhaps only -- factor necessary for mediating neuron-specific alternative splicing of a number of very interesting RNAs," says Darnell.

"CLIP opens a door to studying the function of Nova in the brain," says co-first author Jernej Ule, a graduate fellow in the Darnell lab.

"We can now better ask, for example, how can the loss of one RNA binding protein lead to mental retardation in the Fragile X syndrome?" Darnell says.

In addition to Darnell, Ule and Jensen, co-authors of the Science paper are Matteo Ruggio and Aldo Mele at Rockefeller, and Aljaz Ule at CREED, University of Amsterdam, Netherlands.

This research was supported by the National Institutes of Health, the Howard Hughes Medical Institute, Human Frontiers Science Program and the Cancer Research Institute.

Joseph Bonner | EurekAlert!
Further information:

More articles from Life Sciences:

nachricht Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München

nachricht Second research flight into zero gravity
21.10.2016 | Universität Zürich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>